Advertisement

Iodoazomycin Riboside [l-(5′-iodo-5′- deoxyribofuranosyl)-2-nitroimidazolel, a Hypoxic Cell Marker In Vivo Evaluation in Experimental Tumors

  • L. I. Wiebe
  • D. C. Jette
  • J. D. Chapman
  • R. J. Flanagan
  • B. E. Meeker

Abstract

Radiosensitizers labelled with nuclides which emit gamma rays have been proposed to have clinical value in the detection of radioresistant hypoxic cell populations in tumors [1]. Such a diagnostic procedure would be of value for radiation and/or chemotherapy treatment planning in oncology, and could aid the study and treatment of ischemic tissue in the myocardium and in the brain. However, the sensitizers 4-[82Br]-bromomisonidazole (BrMISO) [2] and l-[2-(2-[131I]iodophenoxy)-ethyl]-2-nitroimidazole (IPENI) [3] failed to undergo selective uptake in experimental tumor models. In both cases, and especially with IPENI, the test substances were more lipophilic than hypoxic cell markers used previously [4]. Recent efforts with tritiated misonidazole to label hypoxic cell fractions in human tumors have provided clinical data which support the concept that hypoxic cells may be detected by scintigraphic methods [5].

Keywords

Hypoxic Cell Tissue Distribution Study Experimental Tumor Model Metabolic Trapping Tissue Distribution Data 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chapman JD, Franko AJ, Sharplin J (1984) A marker for hypoxic cells in tumors with potential clinical applicability. Br J Cancer 43:546CrossRefGoogle Scholar
  2. 2.
    Jette DC, Wiebe LI, Chapman JD (1983) Synthesis and in vivo distribution and metabolism of the radiosensitizer 4-(82Br) bromomisonidazole in tumor-bearing and normal mice. Int J Nucl Med Biol 10:205–210PubMedCrossRefGoogle Scholar
  3. 3.
    Wiebe LI, Jette DC, Chapman JD (1984) Electron-affinic compounds for labelling hypoxic cells: the synthesis and characterization of 1-[2-(2-iodophenoxy)-ethyl]-2-nitroimidazole. Nuklearmedizin 2:63–67Google Scholar
  4. 4.
    Chapman JD, Baer K, Lee J (1983) Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 43:1523–1528PubMedGoogle Scholar
  5. 5.
    Chapman JD et al. Unpublished work in progressGoogle Scholar
  6. 6.
    Jette DC, Wiebe LI, Lee J, Flanagan RJ, Chapman JD (in press) Iodoazomycin riboside [1- (5′-iodo-5′-deoxyribofuranosyl)-2-nitroimidazole], a hypoxic cell marker. 1. In vitro characterization. Rad ResGoogle Scholar
  7. 7.
    Jarvis SM, Chapman JD, Ngan-Lee J, Rutledge KA, Barr PJ, Paterson ARP (1982) Azomycin riboside, a sugar homologue of misonidazole with favorable radiosensitizing properties. Cancer Res 42:4358–4363PubMedGoogle Scholar
  8. 8.
    Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695–712PubMedCrossRefGoogle Scholar
  9. 9.
    Thorndyke C, Meeker BE, Thomas G, Lakey WH, McPhee MS, Chapman JD (1985) The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinoma. J Urol 134Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • L. I. Wiebe
    • 1
  • D. C. Jette
  • J. D. Chapman
  • R. J. Flanagan
  • B. E. Meeker
  1. 1.Faculty of Pharmacy and Pharmaceutical SciencesUniversity of AlbertaEdmontonCanada

Personalised recommendations